{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:03:04Z","timestamp":1792112584642,"version":"4.4.0"},"reference-count":309,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Iron is essential for all living organisms. Many iron-containing proteins and metabolic pathways play a key role in almost all cellular and physiological functions. The diversity of the activity and function of iron and its associated pathologies is based on bond formation with adjacent ligands and the overall structure of the iron complex in proteins or with other biomolecules. The control of the metabolic pathways of iron absorption, utilization, recycling and excretion by iron-containing proteins ensures normal biologic and physiological activity. Abnormalities in iron-containing proteins, iron metabolic pathways and also other associated processes can lead to an array of diseases. These include iron deficiency, which affects more than a quarter of the world\u2019s population; hemoglobinopathies, which are the most common of the genetic disorders and idiopathic hemochromatosis. Iron is the most common catalyst of free radical production and oxidative stress which are implicated in tissue damage in most pathologic conditions, cancer initiation and progression, neurodegeneration and many other diseases. The interaction of iron and iron-containing proteins with dietary and xenobiotic molecules, including drugs, may affect iron metabolic and disease processes. Deferiprone, deferoxamine, deferasirox and other chelating drugs can offer therapeutic solutions for most diseases associated with iron metabolism including iron overload and deficiency, neurodegeneration and cancer, the detoxification of xenobiotic metals and most diseases associated with free radical pathology.<\/jats:p>","DOI":"10.3390\/cells9061456","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T12:16:57Z","timestamp":1592223417000},"page":"1456","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-7340","authenticated-orcid":false,"given":"George","family":"Kontoghiorghes","sequence":"first","affiliation":[{"name":"Postgraduate Research Institute of Science, Technology, Environment and Medicine, CY-3021 Limassol, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kontoghiorghe","sequence":"additional","affiliation":[{"name":"Postgraduate Research Institute of Science, Technology, Environment and Medicine, CY-3021 Limassol, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"ref_1","first-page":"93","article-title":"Zinc: An overview","volume":"11","author":"Prasad","year":"1995","journal-title":"Nutrition"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1146\/annurev.bi.61.070192.004341","article-title":"Zinc Proteins: Enzymes, Storage Proteins, Transcription Factors, and Replication Proteins","volume":"61","year":"1992","journal-title":"Annu. Rev. Biochem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/bmj.326.7386.409","article-title":"Zinc deficiency","volume":"326","author":"Prasad","year":"2003","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.2741\/1424","article-title":"Copper storage diseases: Menkes, Wilsons, and cancer","volume":"9","author":"Daniel","year":"2004","journal-title":"Front. Biosci"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10408360701713104","article-title":"Oxidative Stress and Iron Homeostasis: Mechanistic and Health Aspects","volume":"45","author":"Galaris","year":"2008","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gozzelino, R., and Arosio, P. (2016). Iron Homeostasis in Health and Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010130"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1017\/S1368980008002401","article-title":"Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993\u20132005","volume":"12","author":"McLean","year":"2008","journal-title":"Public Heal. Nutr."},{"key":"ref_8","unstructured":"(1983). Community control of hereditary anaemias: Memorandum from a WHO meeting*. Bull. World Heal. Organ., 61, 63\u201380."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"334","author":"Zurlo","year":"1989","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto","year":"2017","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"Worldwide Network for Blood and Marrow Transplantation. (WBMT). One million haemopoietic stem-cell transplants: A retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2017.01.009","article-title":"Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation","volume":"23","author":"Shenoy","year":"2017","journal-title":"Boil. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/17474086.2019.1647778","article-title":"Novel therapies in low- and high-risk myelodysplastic syndrome","volume":"12","author":"Germing","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17474086.2020.1719359","article-title":"How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?","volume":"13","author":"Kontoghiorghes","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2019.1631284","article-title":"Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology","volume":"28","author":"Kontoghiorghes","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_16","first-page":"118535","article-title":"Iron homeostasis and oxidative stress: An intimate relationship","volume":"1866","author":"Galaris","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Bioenerg"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.bbagen.2019.06.010","article-title":"Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases","volume":"1863","author":"Nakamura","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1039\/C8MT00219C","article-title":"Is copper a new target to counteract the progression of chronic diseases?","volume":"10","author":"Balsano","year":"2018","journal-title":"Metallomics."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Denisov, E.T., and Afanas\u2019Ev, I.B. (2005). Oxidation and Antioxidants in Organic Chemistry and Biology, CRC Press.","DOI":"10.1201\/9781420030853"},{"key":"ref_20","first-page":"598","article-title":"Free radicals, antioxidants, and human disease: Where are we now?","volume":"119","author":"Halliwell","year":"1992","journal-title":"J. Lab. Clin. Med."},{"key":"ref_21","unstructured":"Rice-Evans, C. (1978). Free radicals, oxidant stress and drug action. Iron Chelation in Biochemistry and Medicine, Rechelieu Press."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2020). Advances on Chelation and Chelator Metal Complexes in Medicine. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072499"},{"key":"ref_23","unstructured":"Anderson, F.W., and Hiller, M.C. (1975). Development of Iron Chelators for Clinical Us, DHEW Publication."},{"key":"ref_24","unstructured":"Kontoghiorghes, G.J. (1982). The Design of Orally Active Iron Chelators for the Treatment of Thalassaemia. [Ph.D. Thesis, University of Essex]. Available online: https:\/\/www.pri.ac.cy\/files\/KGJ_thesis_1982.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2174\/0929867043364685","article-title":"The design and development of deferiprone (L1) and other iron chelators for clinical use: Targeting methods and application prospects","volume":"11","author":"Kontoghiorghes","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2174\/092986705774463003","article-title":"Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations","volume":"12","author":"Kontoghiorghes","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_27","first-page":"704","article-title":"Inherited haemoglobin disorders: An increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bull. World Heal. Organ."},{"key":"ref_28","first-page":"95","article-title":"The impact and disease burden of thalassemia in Thailand: A population-based study in 2010","volume":"95","author":"Teawtrakul","year":"2012","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02829934","article-title":"A precious metal: Iron, an essential nutrient for all cells","volume":"1","author":"Cairo","year":"2006","journal-title":"Genes Nutr."},{"key":"ref_30","first-page":"27","article-title":"Red blood cell storage lesion: Causes and potential clinical consequences","volume":"17","author":"Yoshida","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fphys.2018.01607","article-title":"Erythrocyte Aging, Protection via Vesiculation: An Analysis Methodology via Oscillatory Flow","volume":"9","author":"Asaro","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fphys.2013.00365","article-title":"Red blood cell vesiculation in hereditary hemolytic anemia","volume":"4","author":"Alaarg","year":"2013","journal-title":"Front. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0009-8981(97)00148-4","article-title":"Antioxidant defence of red blood cells and plasma in stored human blood","volume":"267","author":"Szczypka","year":"1997","journal-title":"Clin. Chim. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/104454902753759717","article-title":"Hemopexin: Structure, Function, and Regulation","volume":"21","author":"Tolosano","year":"2002","journal-title":"DNA Cell Boil."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ajh.23623","article-title":"Haptoglobin testing in hemolysis: Measurement and interpretation","volume":"89","author":"Shih","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1126\/science.276.5321.2034","article-title":"Blood Flow Regulation by S-Nitrosohemoglobin in the Physiological Oxygen Gradient","volume":"276","author":"Stamler","year":"1997","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1134\/S0006297918020098","article-title":"Myoglobin: Oxygen Depot or Oxygen Transporter to Mitochondria? A Novel Mechanism of Myoglobin Deoxygenation in Cells (review)","volume":"83","author":"Postnikova","year":"2018","journal-title":"Biochemistry (Moscow)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2174\/092986705774463021","article-title":"Hemoglobin and myoglobin associated oxidative stress: From molecular mechanisms to disease States","volume":"12","author":"Reeder","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1089\/ars.2016.6803","article-title":"Redox and Peroxidase Activities of the Hemoglobin Superfamily: Relevance to Health and Disease","volume":"26","author":"Reeder","year":"2017","journal-title":"Antioxid. Redox Signal"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1002\/1873-3468.13655","article-title":"New moonlighting functions of mitochondrial cytochrome c in the cytoplasm and nucleus","volume":"593","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1515\/hsz-2019-0310","article-title":"Coupling of import and assembly pathways in mitochondrial protein biogenesis","volume":"401","author":"Grevel","year":"2019","journal-title":"Boil. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fcell.2019.00100","article-title":"Mitochondria and Inflammation: Cell Death Heats Up","volume":"7","author":"Vringer","year":"2019","journal-title":"Front. Cell Dev. Boil."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ijbiomac.2019.06.180","article-title":"Cytochrome c: An extreme multifunctional protein with a key role in cell fate","volume":"136","author":"Santucci","year":"2019","journal-title":"Int. J. Boil. Macromol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00109-020-01905-y","article-title":"Stress-mediated generation of deleterious ROS in healthy individuals-role of cytochrome c oxidase","volume":"98","author":"Ramzan","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.semcdb.2017.08.055","article-title":"Mitochondrial cytochrome c oxidase biogenesis: Recent developments","volume":"76","author":"Abriata","year":"2018","journal-title":"Semin. Cell Dev. Boil."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Llases, M., Morgada, M.N., and Vila, A.J. (2019). Biochemistry of Copper Site Assembly in Heme-Copper Oxidases: A Theme with Variations. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153830"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.apsb.2019.11.002","article-title":"Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): Therapeutic and pathophysiological implications","volume":"10","author":"Kwon","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 Structure, Function and Clinical Significance: A Review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tornio, A., and Backman, J.T. (2018). Cytochrome P450 in Pharmacogenetics: An Update. Adv. Pharmacol., 3\u201332.","DOI":"10.1016\/bs.apha.2018.04.007"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2174\/1389200023337054","article-title":"The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans","volume":"3","author":"Danielson","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1559S","DOI":"10.3945\/ajcn.117.155804","article-title":"Current understanding of iron homeostasis","volume":"106","author":"Anderson","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MOH.0000000000000132","article-title":"New insights into iron regulation and erythropoiesis","volume":"22","author":"Kim","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.freeradbiomed.2018.03.051","article-title":"NADPH-dependent and -independent disulfide reductase systems","volume":"127","author":"Miller","year":"2018","journal-title":"Free. Radic. Boil. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1039\/C7MT00116A","article-title":"The elemental role of iron in DNA synthesis and repair","volume":"9","author":"Puig","year":"2017","journal-title":"Metallomics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: Biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2014","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200326080-00003","article-title":"Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: Comparison of epidemiological and therapeutic aspects with deferoxamine","volume":"26","author":"Kontoghiorghes","year":"2003","journal-title":"Drug Saf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/03630260701680367","article-title":"Pharmacogenomics and Therapeutics of Hemoglobinopathies","volume":"32","author":"Patrinos","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1126\/science.277.5326.653","article-title":"Iron-Sulfur Clusters: Nature\u2019s Modular, Multipurpose Structures","volume":"277","author":"Beinert","year":"1997","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1039\/C7MT00269F","article-title":"Protein networks in the maturation of human iron\u2013sulfur proteins","volume":"10","author":"Nasta","year":"2018","journal-title":"Metallomics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00775-018-1548-6","article-title":"Iron\u2013sulfur clusters: From metals through mitochondria biogenesis to disease","volume":"23","author":"Chatzi","year":"2018","journal-title":"J. Boil. Inorg. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","article-title":"Transferrin and transferrin receptors update","volume":"133","author":"Kawabata","year":"2019","journal-title":"Free. Radic. Boil. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/acschembio.8b01100","article-title":"Transferrin Cycle and Clinical Roles of Citrate and Ascorbate in Improved Iron Metabolism","volume":"14","author":"Levina","year":"2019","journal-title":"ACS Chem. Boil."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1039\/c8mt00308d","article-title":"Competition between Al3+ and Fe3+ binding to human transferrin and toxicological implications: Structural investigations using ultra-high resolution ESI MS and CD spectroscopy","volume":"11","author":"Ott","year":"2019","journal-title":"Metallomics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10534-018-0142-2","article-title":"Ferric pyrophosphate citrate: Interactions with transferrin","volume":"31","author":"Pratt","year":"2018","journal-title":"BioMetals"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1080\/10408398.2017.1381583","article-title":"Lactoferrin: Structure, function, denaturation and digestion","volume":"59","author":"Wang","year":"2017","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Rosa, L., Cutone, A., Lepanto, M., Paesano, R., and Valenti, P. (2017). Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091985"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/iub.1621","article-title":"Ferritin, cellular iron storage and regulation","volume":"69","author":"Arosio","year":"2017","journal-title":"IUBMB Life"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000496324","article-title":"Storage Iron Turnover from a New Perspective","volume":"141","author":"Saito","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1039\/C7MT00284J","article-title":"Mobilization of iron from ferritin: New steps and details","volume":"10","author":"La","year":"2018","journal-title":"Metallomics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbagen.2010.03.011","article-title":"Serum ferritin: Past, present and future","volume":"1800","author":"Wang","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2174\/092986705774462969","article-title":"Structure\/function overview of proteins involved in iron storage and transport","volume":"12","author":"Sargent","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/13543784.2013.787408","article-title":"Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals","volume":"22","author":"Kontoghiorghe","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1021\/acs.biochem.7b00024","article-title":"Iron Oxidation and Core Formation in Recombinant Heteropolymeric Human Ferritins","volume":"56","author":"Mehlenbacher","year":"2017","journal-title":"Biochemistry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.1021\/ic400484n","article-title":"Ferritin: The Protein Nanocage and Iron Biomineral in Health and in Disease","volume":"52","author":"Theil","year":"2013","journal-title":"Inorg. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0892-0354(92)90011-E","article-title":"Ferritin and hemosiderin in pathological tissues","volume":"5","author":"Iancu","year":"1992","journal-title":"Electron Microsc. Rev."},{"key":"ref_76","first-page":"91","article-title":"An intracellular transit iron pool","volume":"51","author":"Jacobs","year":"1976","journal-title":"Ciba Found. Symp."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"26723","DOI":"10.1074\/jbc.270.45.26723","article-title":"Siderophores: Structure and Function of Microbial Iron Transport Compounds","volume":"270","author":"Neilands","year":"1995","journal-title":"J. Boil. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20841","DOI":"10.3390\/molecules201119725","article-title":"Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology","volume":"20","author":"Kontoghiorghe","year":"2015","journal-title":"Molecules"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.molmed.2016.10.005","article-title":"Siderophores in Iron Metabolism: From Mechanism to Therapy Potential","volume":"22","author":"Wilson","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S529","DOI":"10.1093\/cid\/ciz825","article-title":"The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics","volume":"69","author":"Page","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Huang, H., Liao, D., Dong, Y., and Pu, R. (2020). Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: A systematic review and meta-analysis. Nutr. Rev., pii: nuz071.","DOI":"10.1093\/nutrit\/nuz071"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctim.2019.02.017","article-title":"The effect of quercetin on iron overload and inflammation in \u03b2-thalassemia major patients: A double-blind randomized clinical trial","volume":"46","author":"Hezaveh","year":"2019","journal-title":"Complement. Ther. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejmech.2018.12.016","article-title":"The therapeutic potential of curcumin: A review of clinical trials","volume":"163","author":"Salehi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12325-020-01251-y","article-title":"Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review","volume":"37","author":"Gillessen","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Xie, Y., Zhang, D., Zhang, J., and Yuan, J. (2019). Metabolism, Transport and Drug-Drug Interactions of Silymarin. Molecules, 24.","DOI":"10.3390\/molecules24203693"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1139\/apnm-2017-0583","article-title":"Chronic administration of ellagic acid improved the cognition in middle-aged overweight men","volume":"43","author":"Liu","year":"2018","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1700699","DOI":"10.1002\/mnfr.201700699","article-title":"Gallic Acid and Gallates in Human Health and Disease: Do Mitochondria Hold the Key to Success?","volume":"62","author":"Kosuru","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Van Gorkom, G.N., Lookermans, E.L., Van Elssen, C.H., and Bos, G.M. (2019). The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrition, 11.","DOI":"10.3390\/nu11050977"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jama.2019.21984","article-title":"Vitamin C for Sepsis and Acute Respiratory Failure","volume":"323","author":"Hager","year":"2020","journal-title":"JAMA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/bcpt.12323","article-title":"Elimination of Ascorbic Acid After High-Dose Infusion in Prostate Cancer Patients: A Pharmacokinetic Evaluation","volume":"116","author":"Nielsen","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/mnfr.201200421","article-title":"Health effects of olive oil polyphenols: Recent advances and possibilities for the use of health claims","volume":"57","author":"Covas","year":"2013","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/10408391003698677","article-title":"Polyphenols and Human Health: A Prospectus","volume":"51","author":"Visioli","year":"2011","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/nu5072564","article-title":"Chemopreventive Potential of Flavonoids in Oral Squamous Cell Carcinoma in Human Studies","volume":"5","author":"Iriti","year":"2013","journal-title":"Nutrients"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.foodchem.2010.08.012","article-title":"The molecular basis of working mechanism of natural polyphenolic antioxidants","volume":"125","author":"Leopoldini","year":"2011","journal-title":"Food Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12013-009-9043-x","article-title":"A Review of the Antioxidant Mechanisms of Polyphenol Compounds Related to Iron Binding","volume":"53","author":"Perron","year":"2009","journal-title":"Cell Biochem. Biophys."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10715768609088062","article-title":"In Vitro Screening of Iron Chelators Using Models of Free Radical Damage","volume":"2","author":"Kontoghiorghes","year":"1986","journal-title":"Free. Radic. Res. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1039\/C4FO00007B","article-title":"Reactivity of food phenols with iron and copper ions: Binding, dioxygen activation and oxidation mechanisms","volume":"5","author":"Nkhili","year":"2014","journal-title":"Food Funct."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1054-3589(08)60983-7","article-title":"Antioxidant and chelating properties of flavonoids","volume":"38","author":"Korkina","year":"1997","journal-title":"Adv. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1749-6632.1990.tb24321.x","article-title":"Design, properties and effective use of the oral chelator L1 and other \u03b1- ketohydroxypyridines in the treatment of transfusional iron overload in thalassaemia","volume":"612","author":"Kontoghiorghes","year":"1990","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"ref_100","first-page":"597","article-title":"Redox properties of 8-quinolinol and implications for its mode of action","volume":"6","author":"Chobot","year":"2011","journal-title":"Nat. Prod. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0014-5793(86)80813-4","article-title":"Cytotoxic effects of the lipophilic iron chelator omadine","volume":"204","author":"Kontoghiorghes","year":"1986","journal-title":"FEBS Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/hon.2900040303","article-title":"Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines","volume":"4","author":"Kontoghiorghes","year":"1986","journal-title":"Hematol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/DDDT.S79458","article-title":"Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes","volume":"10","author":"Kontoghiorghe","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.1978.tb03662.x","article-title":"Non-Specific Serum Iron in Thalassaemia: An Abnormal Serum Iron Fraction of Potential Toxicity","volume":"40","author":"Hershko","year":"1978","journal-title":"Br. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.295.6612.1509","article-title":"Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"295","author":"Kontoghiorghes","year":"1987","journal-title":"BMJ"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fphar.2014.00217","article-title":"Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major","volume":"5","author":"Baksi","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0609.2010.01499.x","article-title":"Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone\/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy","volume":"85","author":"Kolnagou","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major","volume":"148","author":"Farmaki","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/s-0043-102691","article-title":"Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination","volume":"67","author":"Kolnagou","year":"2017","journal-title":"Drug Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2741\/4634","article-title":"Chelation protocols for the elimination and prevention of iron overload in thalassaemia","volume":"23","author":"Kolnagou","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e2020011","DOI":"10.4084\/mjhid.2020.011","article-title":"The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia","volume":"12","author":"Kontoghiorghes","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.15595","article-title":"MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine","volume":"183","author":"Pepe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/17474086.2019.1593823","article-title":"Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major \u2013 a pilot study","volume":"12","author":"Lin","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.transci.2019.03.021","article-title":"A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major","volume":"58","author":"Eghbali","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MPH.0000000000001596","article-title":"Evaluation of efficacy, safety, and satisfaction taking deferasirox twice daily versus once daily in patients with transfusion-dependent thalassemia","volume":"42","author":"Karimi","year":"2020","journal-title":"J. Pediatrics Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ejh.13244","article-title":"Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload","volume":"103","author":"Binding","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/20009666.2019.1650592","article-title":"Deferasirox-a rarer cause of Fanconi syndrome","volume":"9","author":"Khan","year":"2019","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5461617-8","DOI":"10.1155\/2019\/5461617","article-title":"Early kidney damage markers after deferasirox treatment in patients with thalassemia major: A case-control study","volume":"2019","author":"Badeli","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MPH.0000000000000780","article-title":"Efficacy and safety of combined oral chelation with deferiprone and deferasirox in children with \u03b2-thalassemia major","volume":"39","author":"Parakh","year":"2017","journal-title":"J. Pediatrics Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/ejh.12939","article-title":"The aim of iron chelation therapy in thalassaemia","volume":"99","author":"Kontoghiorghes","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0300-483X(95)03301-U","article-title":"The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1\u2019ol]-2-methyl-3-hydroxypyridin-4-one in the rat","volume":"108","author":"Fredenburg","year":"1996","journal-title":"Toxicology"},{"key":"ref_122","first-page":"35","article-title":"Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"9","author":"Vreugdenhil","year":"1991","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(89)92011-4","article-title":"Efficacy and safety of the oral chelator L1 in anaemic rheumadoit arthritis patients","volume":"II","author":"Vreughtenhil","year":"1989","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: Biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease","volume":"7","author":"Ward","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/mds.23751","article-title":"Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial","volume":"26","author":"Zorzi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/mds.22002","article-title":"Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation","volume":"23","author":"Forni","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1998.00380.x","article-title":"Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron","volume":"12","author":"Harvey","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/000456320003700405","article-title":"Assessment of iron absorption from ferric trimaltol","volume":"37","author":"Reffitt","year":"2000","journal-title":"Ann. Clin. Biochem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MIB.0000000000000314","article-title":"Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease","volume":"21","author":"Gasche","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_131","first-page":"1332","article-title":"Chelators affecting iron absorption in mice","volume":"40","author":"Kontoghiorghes","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0041-008X(71)90300-0","article-title":"8-hydroxyquinoline: Chronic toxicity and inhibitory effect on the carcinogenicity of N-2- fluorenylacetamide","volume":"19","author":"Yamamoto","year":"1971","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/15376516.2012.730562","article-title":"EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: Review of preliminary findings and risk\/benefit assessment","volume":"23","author":"Born","year":"2012","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/rpd\/ncm299","article-title":"Treatment of human contamination with plutonium and americium: Would orally administered Ca- or Zn-DTPA be effective?","volume":"127","author":"Taylor","year":"2007","journal-title":"Radiat. Prot. Dosim."},{"key":"ref_135","first-page":"35","article-title":"The effect of tetracycline administration on iron absorption in mice","volume":"35","author":"Djaldetti","year":"1981","journal-title":"Biomedicine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/03630269.2011.578950","article-title":"Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: Implications on toxicity and therapeutic strategies","volume":"35","author":"Konstantinou","year":"2011","journal-title":"Hemoglobin"},{"key":"ref_137","first-page":"659","article-title":"Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals","volume":"43","author":"Sheppard","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.2174\/092986705774463030","article-title":"Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: The role of natural and synthetic chelators","volume":"12","author":"Kontoghiorghes","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1258\/0007142991902628","article-title":"Inborn errors of metabolism: Iron","volume":"55","author":"Worwood","year":"1999","journal-title":"Br. Med Bull."},{"key":"ref_140","first-page":"77","article-title":"Relationships among iron accumulation, cirrhosis, and hepatitis B virus infection in Bantu siderosis","volume":"69","author":"Senba","year":"1989","journal-title":"Ann. Soc. Belg. Med. Trop."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1191\/0960327105ht564oa","article-title":"Hepatotoxicity in acute iron poisoning","volume":"24","author":"Robertson","year":"2005","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_142","first-page":"534","article-title":"Acute iron poisoning: Management guidelines","volume":"40","author":"Baranwal","year":"2003","journal-title":"Indian Pediatrics"},{"key":"ref_143","first-page":"243","article-title":"Clinical experience of acute ferric chloride poisoning","volume":"45","author":"Wu","year":"2003","journal-title":"Veter-Hum. Toxicol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1749-6632.1998.tb10523.x","article-title":"Effect of oral iron chelator L1 on iron absorption in man","volume":"850","author":"Dresow","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0735-6757(00)90045-7","article-title":"The efficacy of oral deferiprone in acute iron poisoning","volume":"18","author":"Berkovitch","year":"2000","journal-title":"Am. J. Emerg. Med."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Iyengar, V., Pullakhandam, R., and Nair, K.M. (2010). Dietary ligands as determinants of iron-zinc interactions at the absorptive enterocyte. J. Food Sci., 75.","DOI":"10.1111\/j.1750-3841.2010.01796.x"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3945\/jn.110.125369","article-title":"Polyphenols and phytic acid contribute to the low iron bioavailability from common beans in young women","volume":"140","author":"Petry","year":"2010","journal-title":"J. Nutr."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/09637480903213649","article-title":"Role of oxate, phytate, tannins and cooking on iron bioavailability from foods commonly consumed in Mexico","volume":"61","author":"Sotelo","year":"2009","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2125.1991.tb05525.x","article-title":"Iron supplements: A common cause of drug interactions","volume":"31","author":"Campbell","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtemb.2014.11.005","article-title":"Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium","volume":"30","author":"Jaramillo","year":"2015","journal-title":"J. Trace Elements Med. Boil."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(15)00444-1","article-title":"Carcinogenicity of consumption of red and processed meat","volume":"16","author":"Bouvard","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000205877","article-title":"Orally active alpha-ketohydroxypyridine iron chelators: Effects on iron and other metal mobilisations","volume":"78","author":"Kontoghiorghes","year":"1987","journal-title":"Acta Haematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF02662506","article-title":"T2 relaxation time study of iron overload in b-thalassemia","volume":"6","author":"Mavrogeni","year":"1998","journal-title":"MAGMA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0609.2005.00474.x","article-title":"A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major","volume":"75","author":"Mavrogeni","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2741\/s498","article-title":"New targeted therapies and diagnostic methods for iron overload diseases","volume":"10","author":"Kolnagou","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0168-8278(96)80070-5","article-title":"Variability in hepatic iron concentration measurement from needle-biopsy specimens","volume":"25","author":"Villeneuve","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/15376516.2012.727198","article-title":"Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: Factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*","volume":"23","author":"Kolnagou","year":"2012","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ana.410440121","article-title":"Normal serum iron and ferritin concentrations in patients with Friedreich\u2019s ataxia","volume":"44","author":"Wilson","year":"1998","journal-title":"Ann Neurol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/bj2330299","article-title":"Iron mobilization from ferritin using \u03b1-oxohydroxy heteroaromatic chelators","volume":"233","author":"Kontoghiorghes","year":"1986","journal-title":"Biochem. J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/bj2410087","article-title":"Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators","volume":"241","author":"Kontoghiorghes","year":"1987","journal-title":"Biochem. J."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0020-1693(00)81178-0","article-title":"Decrease solubilisation of ferritin iron and fresh iron(III) precipitate following repeated chelator treatments","volume":"138","author":"Kontoghiorghes","year":"1987","journal-title":"Inorg. Chim. Acta"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/clpt.1990.147","article-title":"Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"48","author":"Kontoghiorghes","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.V79.10.2741.bloodjournal79102741","article-title":"Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia","volume":"79","author":"Olivieri","year":"1992","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0005-2795(76)90270-1","article-title":"The detection of four molecular forms of human transferrin during the iron binding process","volume":"453","author":"Makey","year":"1976","journal-title":"Biochim. Biophys. Acta (BBA)-Protein Struct."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1359-6446(04)03333-1","article-title":"Transferrin: Structure, function and potential therapeutic actions","volume":"10","author":"Gomme","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood-2014-12-617571","article-title":"TfR2 links iron metabolism and erythropoiesis","volume":"125","author":"Pantopoulos","year":"2015","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dkz225","article-title":"Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria","volume":"74","author":"Luna","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_168","first-page":"pii: e02284","article-title":"Lactoferrin Is Broadly Active against Yeasts and Highly Synergistic with Amphotericin B","volume":"64","author":"Fernandes","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_169","first-page":"301.e1","article-title":"Lactoferrin: Structure, function and applications","volume":"33","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0167-4838(86)90288-8","article-title":"The study of iron mobilisation from transferrin using \u03b1-ketohydroxy heteroaromatic chelators","volume":"869","author":"Kontoghiorghes","year":"1986","journal-title":"Biochim. Biophys. Acta (BBA)-Protein Struct. Mol. Enzym."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-4165(86)90164-9","article-title":"Iron mobilisation from lactoferrin by chelators at physiological pH","volume":"882","author":"Kontoghiorghes","year":"1986","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"L11","DOI":"10.1016\/S0020-1693(00)85549-8","article-title":"Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones","volume":"136","author":"Kontoghiorghes","year":"1987","journal-title":"Inorg. Chim. Acta"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ajh.2830420403","article-title":"Selection of a new generation of orally active \u03b1-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload","volume":"42","author":"Kontoghiorghes","year":"1993","journal-title":"Am. J. Hematol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0014-5793(85)80859-0","article-title":"Site specificity of iron removal from transferrin by \u03b1-ketohydroxypyridine chelators","volume":"189","author":"Kontoghiorghes","year":"1985","journal-title":"FEBS Lett."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/03630260600642450","article-title":"Iron mobilization from transferrin and non-transferrin bound iron by deferiprone. Implications in the treatment of thalassaemia, anaemia of chronic disease, cancer and other conditions","volume":"30","author":"Kontoghiorghes","year":"2006","journal-title":"Hemoglobin"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"L35","DOI":"10.1016\/S0020-1693(00)84710-6","article-title":"Mobilisation of plutonium and iron from transferrin and ferritin by \u03b1-oxohydroxypyridine chelators","volume":"125","author":"Taylor","year":"1986","journal-title":"Inorg. Chim. Acta Bioinorg Chem."},{"key":"ref_177","first-page":"9","article-title":"The effect of \u03b1-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo","volume":"28","author":"Evans","year":"1992","journal-title":"Drugs Today"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/03630260903217182","article-title":"A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients","volume":"33","author":"Kontoghiorghes","year":"2009","journal-title":"Hemoglobin"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5662\/wjm.v6.i1.1","article-title":"New developments and controversies in iron metabolism and iron chelation therapy","volume":"6","author":"Kontoghiorghe","year":"2016","journal-title":"World J. Methodol."},{"key":"ref_180","first-page":"183","article-title":"Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells","volume":"3","author":"Kontoghiorghes","year":"1990","journal-title":"BioMetals"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V48.6.923.923","article-title":"The effect of chelating agents on iron mobilization in Chang cell cultures","volume":"48","author":"White","year":"1976","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0609.1987.tb00776.x","article-title":"Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexes","volume":"39","author":"Forsbeck","year":"1987","journal-title":"Eur. J. Haematol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0020-1693(00)91889-9","article-title":"Structure\/red blood cell permeability. Activity of iron(III) chelator complexes","volume":"151","author":"Kontoghiorghes","year":"1988","journal-title":"Inorg. Chim. Acta"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bbagen.2010.02.005","article-title":"Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage","volume":"1800","author":"Arosio","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2013.07.005","article-title":"Mitochondrial ferritin in neurodegenerative diseases","volume":"77","author":"Yang","year":"2013","journal-title":"Neurosci. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10715768709088079","article-title":"Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte","volume":"3","author":"Mostert","year":"1987","journal-title":"Free. Radic. Res. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/03630269.2011.576153","article-title":"Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy","volume":"35","author":"Kolnagou","year":"2011","journal-title":"Hemoglobin"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1007049701572","article-title":"Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study","volume":"204","author":"Chakraborty","year":"2000","journal-title":"Mol. Cell. Biochem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s11033-014-3021-0","article-title":"Deferiprone: Structural and functional modulating agent of hemoglobin fructation","volume":"41","author":"Sattarahmady","year":"2014","journal-title":"Mol. Boil. Rep."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1021\/ja3032949","article-title":"Redox-linked changes to the hydrogen-bonding network of ribonucleotide reductase \u03b22","volume":"135","author":"Offenbacher","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1574892811666160926143534","article-title":"Modeling and proposed molecular mechanism of hydroxyurea through docking and molecular dynamic simulation to curtail the action of ribonucleotide reductase","volume":"11","author":"Iman","year":"2016","journal-title":"Recent Patents Anti-Cancer Drug Discov."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.seminhematol.2018.04.008","article-title":"Fetal hemoglobin induction by epigenetic drugs","volume":"55","author":"Lavelle","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3109\/08880010903271671","article-title":"Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: Case series and review of literature","volume":"26","author":"Ehsani","year":"2009","journal-title":"Pediatrics Hematol. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"102327","DOI":"10.1016\/j.ctim.2020.102327","article-title":"Review\/overview of pain in sickle cell disease","volume":"49","author":"Ballas","year":"2020","journal-title":"Complement. Ther. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00277-020-03977-9","article-title":"Pathophysiology and recent therapeutic insights of sickle cell disease","volume":"99","author":"Shah","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Nardo-Marino, A., Brousse, V., and Rees, D.C. (2020). Emerging therapies in sickle cell disease. Br. J. Haematol.","DOI":"10.1111\/bjh.16504"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3324\/haematol.2018.207357","article-title":"Emerging disease-modifying therapies for sickle cell disease","volume":"104","author":"Carden","year":"2019","journal-title":"Haematologica"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12098-019-03065-5","article-title":"Thalassemia: Common clinical queries in management","volume":"87","author":"Lal","year":"2019","journal-title":"Indian J. Pediatrics"},{"key":"ref_199","first-page":"e18","article-title":"Safety and effectiveness of thalidomide and hydroxyurea combination in \u03b2-thalassaemia intermedia and major: A retrospective pilot study","volume":"188","author":"Shah","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Fraser, D.I., Liu, K.T., Reid, B.J., Hawkins, E., Sevier, A., Pyle, M., Robinson, J.W., Ouellette, P.H.R., and Ballantyne, J.S. (2015). Widespread natural occurrence of hydroxyurea in animals. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142890"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Manaresi, E., and Gallinella, G. (2019). Advances in the development of antiviral strategies against parvovirus B19. Viruses, 11.","DOI":"10.3390\/v11070659"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11899-020-00564-7","article-title":"Novel therapies in polycythemia vera","volume":"15","author":"Tremblay","year":"2020","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10787-009-0016-x","article-title":"Ibuprofen: Pharmacology, efficacy and safety","volume":"17","author":"Rainsford","year":"2009","journal-title":"Inflammopharmacology"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"111046","DOI":"10.1016\/j.jinorgbio.2020.111046","article-title":"Synthesis, chemical characterization and DNA interaction study of new diclofenac and ibuprofen zinc (II)-nicotinamide ternary complexes as cyclooxygenase inhibitor prototypes","volume":"206","author":"Pich","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb. Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois","year":"1998","journal-title":"FASEB J."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1042\/bj2540239","article-title":"The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro","volume":"254","author":"Jeremy","year":"1988","journal-title":"Biochem. J."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1389200043335531","article-title":"Cytochrome P450 and liver diseases","volume":"5","author":"Villeneuve","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.freeradbiomed.2013.01.026","article-title":"Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by \"antioxidant\" metal chelators: From ferroptosis to stroke","volume":"62","author":"Speer","year":"2013","journal-title":"Free. Radic. Boil. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.semnuclmed.2008.08.002","article-title":"Clinically Proven Radiopharmaceuticals for Infection Imaging: Mechanisms and Applications","volume":"39","author":"Goldsmith","year":"2009","journal-title":"Semin. Nucl. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/bi00403a033","article-title":"Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin","volume":"27","author":"Zak","year":"1988","journal-title":"Biochemistry"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00006231-200404000-00012","article-title":"99mTc-labelled human serum transferrin for tumour imaging: An in vitro and in vivo study of the complex","volume":"25","author":"Smith","year":"2004","journal-title":"Nucl. Med. Commun."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jlcr.3388","article-title":"A study of radiogallium aqueous chemistry: In vitro and in vivo characterisation of 67 Ga-hydrolysed-stannous fluoride particles","volume":"59","author":"Tsopelas","year":"2016","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3109\/00365521.2012.696682","article-title":"In-111 transferrin scintigraphy in cirrhosis with hypoalbuminemia: Evidence for protein-losing enteropathy in a small group of selected cases","volume":"47","author":"Jamar","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1040-8428(01)00225-6","article-title":"Gallium in cancer treatment","volume":"42","author":"Collery","year":"2002","journal-title":"Crit. Rev. Oncol."},{"key":"ref_216","first-page":"1103","article-title":"Metal complexes of ruthenium: A potential class of selective anticancer drugs","volume":"11","author":"Sava","year":"1991","journal-title":"Anticancer. Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"45597","DOI":"10.18632\/oncotarget.17316","article-title":"Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(82)90544-X","article-title":"Treatment of dialysis osteomalacia with desferrioxamine","volume":"320","author":"Brown","year":"1982","journal-title":"Lancet"},{"key":"ref_219","first-page":"522","article-title":"Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one","volume":"44","author":"Kontoghiorghes","year":"1994","journal-title":"Arzn Forsch Drug Res"},{"key":"ref_220","first-page":"169","article-title":"Retention of injected plutonium and americium in mice and rats after oral treatment with DTPA, desferrioxamine and alpha-ketohydroxypyridines","volume":"28","author":"Volf","year":"1992","journal-title":"Drugs Today"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02345915","article-title":"Effective complex formation in the interaction of I,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with Uranium (VI)","volume":"242","author":"Pashalidis","year":"1999","journal-title":"J. Radioanalyt. Nucl. Chem."},{"key":"ref_222","first-page":"161","article-title":"Prospects for introducing deferiprone as potent pharmaceutical antioxidant","volume":"1","author":"Kontoghiorghes","year":"2009","journal-title":"Front. Biosci. (Elite Ed)"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2741\/4253","article-title":"Antioxidant targeting by deferiprone in diseases related to oxidative damage","volume":"19","author":"Kontoghiorghe","year":"2014","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.freeradbiomed.2016.07.003","article-title":"Redox signaling: An evolution from free radicals to aging","volume":"97","author":"Forman","year":"2016","journal-title":"Free Radic Biol Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"26505","DOI":"10.1074\/jbc.R113.457564","article-title":"Regulation of circadian clocks by redox homeostasis","volume":"288","author":"Stangherlin","year":"2013","journal-title":"J. Boil. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Arevalo, J.A., and Vazquez-Medina, J.P. (2018). The role of peroxiredoxin 6 in cell signaling. Antioxidants., 7.","DOI":"10.3390\/antiox7120172"},{"key":"ref_227","first-page":"459","article-title":"Some current insights into oxidative stress","volume":"59","year":"2009","journal-title":"Physiol. Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/clinchem\/41.12.1819","article-title":"Lipid peroxidation and antioxidants as biomarkers of tissue damage","volume":"41","author":"Gutteridge","year":"1995","journal-title":"Clin. Chem."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00726-003-0011-2","article-title":"Free radical-mediated oxidation of free amino acids and amino acid residues in proteins","volume":"25","author":"Stadtman","year":"2003","journal-title":"Amino Acids"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Feng, H., and Stockwell, B.R. (2018). Unsolved mysteries: How does lipid peroxidation cause ferroptosis?. PLoS Boil., 16.","DOI":"10.1371\/journal.pbio.2006203"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/acscentsci.7b00589","article-title":"Resolving the role of lipoxygenases in the initiation and execution of ferroptosis","volume":"4","author":"Shah","year":"2018","journal-title":"ACS Central Sci."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fnins.2018.00214","article-title":"Oxytosis\/ferroptosis\u2014(re-) emerging roles for oxidative stress-dependent non-apoptotic cell death in diseases of the central nervous system","volume":"12","author":"Lewerenz","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_233","first-page":"5405","article-title":"Metabolic networks in ferroptosis","volume":"15","author":"Hao","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-642-74936-0_37","article-title":"Influence of iron chelators, 1,2-dialkyl-3-hydroxypyridin-4-ones, on the lipid peroxidation and glutathione level in the liver of mice","volume":"14","author":"Eybl","year":"1991","journal-title":"Arch. Toxicol. Suppl."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11064-014-1508-7","article-title":"Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone","volume":"40","author":"Maher","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/15376516.2012.730558","article-title":"Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease","volume":"23","author":"Rajapurkar","year":"2012","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jmri.21563","article-title":"MRI assessment of basal ganglia iron deposition in Parkinson\u2019s disease","volume":"28","author":"Wallis","year":"2008","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/archneurol.2008.586","article-title":"Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism","volume":"66","author":"Brar","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H","article-title":"Increased iron in the dentate nucleus of patients with Friedrich\u2019s ataxia","volume":"46","author":"Waldvogel","year":"1999","journal-title":"Ann Neurol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.taap.2017.11.005","article-title":"Deferiprone inhibits iron overload-induced tissue factor bearing endothelial microparticle generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis","volume":"338","author":"Chan","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/0024-3205(92)90279-X","article-title":"Iron depletion: A defense against intracellular infection and neoplasm","volume":"50","author":"Weinberg","year":"1992","journal-title":"Life Sci."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0168-6445(03)00055-X","article-title":"Bacterial iron homeostasis","volume":"27","author":"Andrews","year":"2003","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0268-960X(95)90038-1","article-title":"Iron: Mammalian defense systems, mechanisms of disease, and chelation therapy approaches","volume":"9","author":"Kontoghiorghes","year":"1995","journal-title":"Blood Rev."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/03630269.2010.483662","article-title":"The role of iron and chelators on infections in iron overload and non iron loaded conditions: Prospects for the design of new antimicrobial therapies","volume":"34","author":"Kontoghiorghes","year":"2010","journal-title":"Hemoglobin"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5662\/wjm.v4.i3.163","article-title":"World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients","volume":"4","author":"Kontoghiorghe","year":"2014","journal-title":"World J. Methodol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(12)61320-8","article-title":"New global estimates of malaria deaths","volume":"380","author":"Lynch","year":"2012","journal-title":"Lancet"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/S0140-6736(12)60488-7","article-title":"Loss of malarial susceptibility to artemisinin in Thailand","volume":"379","author":"Uhlemann","year":"2012","journal-title":"Lancet"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood.V79.2.308.308","article-title":"Iron chelation with desferrioxamine B in adults with asymptomatic P. Falciparum parasitemia","volume":"79","author":"Gordeuk","year":"1992","journal-title":"Blood"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V72.1.358.358","article-title":"Antimalarial properties of orally active iron chelators","volume":"72","author":"Heppner","year":"1988","journal-title":"Blood"},{"key":"ref_250","first-page":"25","article-title":"Growth inhibition of Plasmodium Falciparum by orally active iron chelators","volume":"28","author":"Mastrandrea","year":"1992","journal-title":"Drugs Today."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1046\/j.1365-2141.2001.03159.x","article-title":"Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum","volume":"115","author":"Goudeau","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_252","first-page":"17","article-title":"Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria","volume":"115","author":"Mohanty","year":"2002","journal-title":"Indian J. Med Res."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(83)91136-4","article-title":"Desferrioxamine and systemic yersiniosis","volume":"322","author":"Prpic","year":"1983","journal-title":"Lancet"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0272-6386(12)80606-8","article-title":"Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry","volume":"18","author":"Boelaert","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","article-title":"Deferiprone iron chelation as a novel therapy for experimental mucormycosis","volume":"58","author":"Ibrahim","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1574-6968.1988.tb02490.x","article-title":"The effect of synthetic iron chelators on bacterial growth in human serum","volume":"1","author":"Brock","year":"1988","journal-title":"FEMS Microbiol. Immunol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2165\/00003495-198529040-00002","article-title":"Ciclopirox olamine 1% cream a preliminary review of its antimicrobial activity and therapeutic use","volume":"29","author":"Jue","year":"1985","journal-title":"Drugs"},{"key":"ref_259","first-page":"140","article-title":"Zinc pyrithione: A topical antimicrobial with complex pharmaceutics","volume":"15","author":"Schwartz","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/03630260701727119","article-title":"Chelators controlling metal metabolism and toxicity pathways: Applications in cancer prevention, diagnosis and treatment","volume":"32","author":"Kontoghiorghes","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"490","DOI":"10.7326\/0003-4819-120-6-199403150-00008","article-title":"Iron-chelating agents in non-iron overload conditions","volume":"120","author":"Voest","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nyas.13008","article-title":"Iron and cancer: Recent insights","volume":"1368","author":"Manz","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"18748","DOI":"10.18632\/oncotarget.4349","article-title":"Targeting cancer by binding iron: Dissecting cellular signaling pathways","volume":"6","author":"Lui","year":"2015","journal-title":"Oncotarget"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2005.12.009","article-title":"Free radicals, metals and antioxidants in oxidative stress-induced cancer","volume":"160","author":"Valko","year":"2006","journal-title":"Chem. Interact."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1039\/C6MT00105J","article-title":"Copper and conquer: Copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics","volume":"8","author":"Park","year":"2016","journal-title":"Metallomics"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/annonc\/mdn775","article-title":"Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"20","author":"Nutting","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.2174\/092986705774462996","article-title":"Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer","volume":"12","author":"Richardson","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_268","first-page":"29","article-title":"Cytotoxic mechanisms of iron chelators","volume":"28","author":"Ganeshaguru","year":"1992","journal-title":"Drugs Today"},{"key":"ref_269","first-page":"173","article-title":"Interaction of L1, L1NAll and desferoxamine with Gallium in vivo","volume":"28","author":"Eybl","year":"1992","journal-title":"Drugs Today."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4155\/fmc.12.69","article-title":"Gallium-containing anticancer compounds","volume":"4","author":"Chitambar","year":"2012","journal-title":"Futur. Med. Chem."},{"key":"ref_271","first-page":"35","article-title":"Inhibition of cycloxygenase and lipoxygenase activity by iron chelators:possible use in the treatment of eicosanoid-related disorders","volume":"28","author":"Jeremy","year":"1992","journal-title":"Drugs Today."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0959-8049(95)00068-T","article-title":"Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary results","volume":"31","author":"Donfrancesco","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5662\/wjm.v4.i4.197","article-title":"Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases","volume":"4","author":"Kolnagou","year":"2014","journal-title":"World J. Methodol."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Timoshnikov, V.A., Kobzeva, T., Polyakov, N.E., and Kontoghiorghes, G.J. (2020). Redox interactions of vitamin C and iron: Inhibition of the pro-oxidant activity by deferiprone. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113967"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2018.09.041","article-title":"Ascorbate and ferritin interactions: Consequences for iron release in vitro and in vivo and implications for inflammation","volume":"133","author":"Naftalin","year":"2019","journal-title":"Free. Radic. Boil. Med."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1039\/C9MT00152B","article-title":"Low-molecular-mass iron complexes in blood plasma of iron-deficient pigs do not originate directly from nutrient iron","volume":"11","author":"Dziuba","year":"2019","journal-title":"Metallomics"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bcp.2017.12.001","article-title":"Dopamine promotes cellular iron accumulation and oxidative stress responses in macrophages","volume":"148","author":"Dichtl","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2018.01811","article-title":"Novel iron-chelator DIBI inhibits Staphylococcus aureus growth, suppresses experimental MRSA infection in mice and enhances the activities of diverse antibiotics in vitro","volume":"9","author":"Parquet","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/03630260701727085","article-title":"Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine\/deferiprone combination. identification of effective chelation therapy protocols","volume":"32","author":"Kolnagou","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1474-4422(19)30142-5","article-title":"Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: A randomised, double-blind, controlled trial and an open-label extension study","volume":"18","author":"Klopstock","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(19)30069-9","article-title":"Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): A multicentre, randomised, placebo-controlled, double-blind phase 2 trial","volume":"18","author":"Selim","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.freeradbiomed.2018.04.002","article-title":"Brain mitochondrial iron accumulates in Huntington\u2019s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically","volume":"120","author":"Agrawal","year":"2018","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Tosato, M., and Di Marco, V. (2019). Metal Chelation Therapy and Parkinson\u2019s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs. Biomolecules, 9.","DOI":"10.3390\/biom9070269"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnins.2019.00180","article-title":"Iron in neurodegeneration\u2013cause or consequence?","volume":"13","author":"Ndayisaba","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Saxena, D., Spino, M., Tricta, F., Connelly, J., Cracchiolo, B.M., Hanauske, A.-R., Gandolfi, D.D., Mathews, M.B., Karn, J., and Holland, B. (2016). Drug-based lead discovery: The novel ablative antiretroviral profile of deferiprone in HIV-1-infected cells and in HIV-infected treatment-naive subjects of a double-blind, placebo-controlled, randomized exploratory trial. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154842"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"11632","DOI":"10.1038\/s41598-017-11899-2","article-title":"Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancer","volume":"7","author":"Leftin","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ajh.2830340106","article-title":"Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages","volume":"34","author":"Brock","year":"1990","journal-title":"Am. J. Hematol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2017.04.005","article-title":"Targeting free radicals in oxidative stress-related human diseases","volume":"38","author":"Poprac","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_289","doi-asserted-by":"crossref","unstructured":"Gaur, K., V\u00e1zquez, A.M., Duran-Camacho, G., Dominguez-Martinez, I., Benjam\u00edn-Rivera, J.A., Fern\u00e1ndez-Vega, L., Sarabia, L.C., Garc\u00eda, A.C., P\u00e9rez-Deliz, F., and Rom\u00e1n, J.M. (2018). Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy. Inorganics, 6.","DOI":"10.3390\/inorganics6040126"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2019.08.007","article-title":"Iron and lung cancer","volume":"464","author":"Kuang","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yu, L., Ding, J., and Chen, Y. (2018). Iron Metabolism in Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010095"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1089\/ars.2017.7487","article-title":"Anticancer thiosemicarbazones: Chemical properties, interaction with iron metabolism, and resistance development","volume":"30","author":"Heffeter","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s10637-018-0703-9","article-title":"A phase I study of the safety and tolerability of VLX600, an iron chelator, in patients with refractory advanced solid tumors","volume":"37","author":"Mody","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtemb.2019.06.008","article-title":"Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy","volume":"55","author":"Barile","year":"2019","journal-title":"J. Trace Elem. Med. Boil."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fonc.2019.00437","article-title":"A Dose escalation study of trientine plus carboplatin and pegylated liposomal doxorubicin in women with a first relapse of epithelial ovarian, tubal, and peritoneal cancer within 12 months after platinum-based chemotherapy","volume":"9","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00775-019-01650-9","article-title":"Effective inhibition of copper-catalyzed production of hydroxyl radicals by deferiprone","volume":"24","author":"Timoshnikov","year":"2019","journal-title":"J. Boil. Inorg. Chem."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000496089","article-title":"Iron chelation as novel treatment for interstitial cystitis","volume":"103","author":"Hagn","year":"2019","journal-title":"Pharmacology"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2174\/1389450119666180605112235","article-title":"Pathological roles of iron in cardiovascular disease","volume":"19","author":"Kobayashi","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1672S","DOI":"10.3945\/ajcn.117.156034","article-title":"Dietary iron intake, iron status, and gestational diabetes","volume":"106","author":"Zhang","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s12098-019-03068-2","article-title":"Comparison of therapeutic efficacy of ferrous ascorbate and iron polymaltose complex in iron deficiency anemia in children: A randomized controlled trial","volume":"86","author":"Patil","year":"2019","journal-title":"Indian J. Pediatrics"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s12098-019-03107-y","article-title":"Treating iron deficiency anemia","volume":"86","author":"Chandra","year":"2019","journal-title":"Indian J. Pediatrics"},{"key":"ref_302","unstructured":"W\u0119gier, L.P., Kubiak, M., Liebert, A., Clavel, T., Montagne, A., Stennevin, A., Roye, S., and Boudribila, A. (2020). Ferrous sulfate oral solution in young children with iron deficiency anemia. Pediatrics Int."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3324\/haematol.2019.220830","article-title":"Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women","volume":"105","author":"Stoffel","year":"2019","journal-title":"Haematologica"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00775-014-1211-9","article-title":"Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins","volume":"20","author":"Enyedy","year":"2014","journal-title":"J. Boil. Inorg. Chem."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4155\/ppa-2018-0016","article-title":"Gallium-68: Methodology and novel radiotracers for positron emission tomography (2012\u20132017)","volume":"7","author":"Tanzey","year":"2018","journal-title":"Pharm. Pat. Anal."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1039\/C9CC01816F","article-title":"A gadolinium-complex-based theranostic prodrug for in vivo tumour-targeted magnetic resonance imaging and therapy","volume":"55","author":"Yang","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/092986705774462987","article-title":"Chelators as antidotes of metal toxicity: Therapeutic and experimental aspects","volume":"12","author":"Blanusa","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_308","first-page":"501","article-title":"Heavy metal induced oxidative stress & its possible reversal by chelation therapy","volume":"128","author":"Flora","year":"2008","journal-title":"Indian J. Med Res."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.2174\/092986705774462978","article-title":"Regulatory molecules and chelators used for the control of essential and toxic metals in health and disease: From molecular interactions to clinical effects and applications","volume":"12","author":"Kontoghiorghes","year":"2005","journal-title":"Curr. Med. Chem."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1456\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:38:07Z","timestamp":1760175487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":309,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cells9061456"],"URL":"https:\/\/doi.org\/10.3390\/cells9061456","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}